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TNF-like ligand 1A (TL1A), which binds its cognate receptor DR3 and the decoy receptor DcR3, is an identifiedmember of the TNF
superfamily. TL1A exerts pleiotropic effects on cell proliferation, activation, and differentiation of immune cells, including helper T
cells and regulatory T cells. TL1A and its two receptors expression is increased in both serum and inflamed tissues in autoimmune
diseases such as inflammatory bowel disease (IBD), rheumatoid arthritis (RA), and ankylosing spondylitis (AS). Polymorphisms of
the TNFSF15 gene that encodes TL1A are associated with the pathogenesis of irritable bowel syndrome, leprosy, and autoimmune
diseases, including IBD, AS, and primary biliary cirrhosis (PBC). In mice, blocking of TL1A-DR3 interaction by either antagonistic
antibodies or deletion of the DR3 gene attenuates the severity of multiple autoimmune diseases, whereas sustained TL1A expression
on T cells or dendritic cells induces IL-13-dependent small intestinal inflammation. This suggests that modulation of TL1A-DR3
interaction may be a potential therapeutic target in several autoimmune diseases, including IBD, RA, AS, and PBC.
1. Characteristics of TL1A and DR3
1.1. TL1A. TL1A, also referred to as vascular endothelial
growth inhibitor (VEGI)-251, is a member of the tumor
necrosis factor superfamily (TNFSF) of ligands, which was
identified by Migone et al. in 2002 [1]. Although TL1A was
identified as a longer variant of TL1/VEGI, the fourth exon of
TL1A encodes the majority of TL1/VEGI, and it has been pre-
sumed that the original TL1/VEGI was a cloning artifact.
TL1A exhibits approximately 20–30% homology to other
TNFSF members [1]. Human TL1A consists of 251 amino
acids: 35 in the cytoplasmic domain, 24 in the transmembrane
region, and 192 in the extracellular domain. There are two
potential N-linked glycosylation sites in the TL1A amino
acid sequence, specifically Asn residues at amino acids 133
and 229 [1]. TL1A is a type II transmembrane protein. TL1A
is initially expressed as a membrane-bound protein and is
subsequently released as a soluble protein via ectodomain
shedding by a metalloproteinase such as TNF-𝛼 converting
enzyme (TACE) [2, 3]. TL1A expression is detected on human
umbilical vein endothelial cells and synovial fibroblast-like
cells and is upregulated by stimulation with proinflammatory
cytokines such as TNF-𝛼, IL-1, and PMA, a phorbol ester
known to be a potent activator of protein kinase C [1, 4]. TL1A
expression has also been confirmed on antigen-presenting
cells and lymphocytes that are activated by Toll-like receptor
(TLR) ligands, enteric bacteria, and Fc𝛾 receptor (Fc𝛾R)
crosslinking [5–7].
1.2. DR3. DR3, also known as APO-3, TRAMP, LARD, and
WSL-1, is a member of the tumor necrosis factor receptor
superfamily (TNFRSF) with a typical death domain that
consists of an approximately 60-amino-acid globular bundle
of 6 conserved 𝛼 helices found in the cytoplasmic region.
Although DR3 is most homologous to TNFR1, which is
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widely expressed, its expression is mostly restricted to lym-
phocytes such as NK cells and T cells, in particular NKT cells
and is enhanced upon their activation [8–10]. DR3 is more
highly expressed onTh17 cells than onTh1 andTh2 cells, and
is also expressed on naturally occurring and TGF-𝛽-induced
Treg cells (n-Treg and i-Treg, resp.) [11–13]. It was recently
shown that DR3 expression on B cells was induced by anti-
IgM stimulation, although its expression was not detectable
on resting B cells [14].There are several expression differences
between human and mouse [9]. DR3 splicing variants of 13
in human [8, 15, 16] and 3 in mice [17] have been identified.
Pappu et al. showed that DR3 splicing variants are differen-
tially expressed on T-cell subsets in mice [13].
2. Role of TL1A-DR3 Signaling in Cell Fate
Determination
TL1A-DR3 signaling induces both NF-𝜅B activation and
apoptosis in vitro [1, 18, 19]. TL1A-DR3 interaction induces
the formation of signaling complexes containing TRADD,
TRAF2, and RIP and activates the NF-𝜅B and MAPK path-
ways (ERK, p38, and JNK). The activation of NF-𝜅B induces
c-IAPs, which protect against apoptosis [20]. On the other
hand, DR3 overexpression in embryonic cells also induces
FADD- and caspase-8-dependent apoptosis [21, 22]. Blocking
of TL1A-DR3 signaling by addingNF-𝜅B inhibitors or protein
synthesis inhibitors induces apoptosis [20], suggesting that
NF-𝜅B activation by TL1A-DR3 interaction is responsible for
resistance to apoptosis. Analysis of DR3-deficient mice has
shown that DR3 is required for negative selection in the thy-
mus [23]. Inhibition of TL1A-DR3 interaction has shown that
TL1A-DR3 signaling is required for effective T-cell immune
responses in the target organs of T-cell-mediated autoim-
mune diseases and inflammatory diseases [24]. Thus, TL1A-
DR3 signaling may be involved in lymphocyte homeostasis
by modulating either cell death or lymphocyte activation.
3. Role of TL1A and DR3 Signaling in
the Immune System
3.1.Th1. UnderTCR stimulation, TL1A induces cell prolifera-
tion and the secretion of proinflammatory cytokines (includ-
ing IFN-𝛾, GM-CSF, and TNF-𝛼) in T cells, in particular
memory CD4+ T cells [1, 25]. Sustained TL1A expression
on T cells or dendritic cells leads to an increase in the
number of activated CD4+ T cells and memory CD4+ T
cells, whereas sustained TL1A expression on dendritic cells
does not stimulate conventional T cells in the absence of
TCR stimulation in vivo, suggesting that TL1A may act as a
costimulator for T cells to regulate inflammatory cytokines
and cell proliferation [26, 27]. TL1A synergizes with IL-
12/IL-18 to promote IFN-𝛾 production in T cells in an
antigen-independent manner [25, 28]. TL1A itself cannot
directly induce Th1 differentiation of native CD4+ T cells,
while TL1A-deficient mice show the decrease of IFN-𝛾-
producing CD4+ T cells [13]. Collectively, it is speculated
that TL1A indirectly or synergistically with other cytokines
enhances Th1 responses of activated and memory CD4+ T
cells. The differential T-cell responsiveness for TL1A between
näıve and activated/memory T cells might be explained by
the regulation of DR3 splicing variants, in particular full-
length transmembrane variant, which encodes complete
transmembrane DR3 protein. The expression of full-length
DR3 mRNA and protein is low level or not detected in naı̈ve
and resting T cells [8], whereas it is upregulated in activated T
cells [9, 25, 29]. Inmice with chronic intestinal inflammation,
the transmembrane DR3 expression is upregulated [25].
3.2. Th17. Although exogenous TL1A induces IL-2 secretion
and responsiveness in T cells [1, 24], IL-2 is a negative regula-
tor forTh17 cells [30].Therefore, when IL-2 is blocked, exoge-
nous TL1A induces the differentiation ofTh17 cells fromnäıve
CD4+ T cells stimulated with TCR under Th17 polarization
condition in vitro. TL1A also induces the proliferation of in-
vitro-differentiated Th17 effector cells but neither Th1 nor
Treg cells even in the absence of TCR stimulation [11, 13].This
differential TL1A responsiveness in T-cell subset might be
explained by DR3 expression. DR3 expression is upregulated
at a later stage but not early stage of Th17 differentiation.
Total DR3 expression is increased in Th17 cells as compared
with Th1 and Th2 cells, and full-length transmembrane DR3
expression is increased in Th17 cells as compared with Treg
cells [13]. Thus, TL1A-DR3 interaction might preferentially
act on Th17 cells and differentially affect the differentiation
and maturation of Th17 cells. On the other hand, TL1A
inhibits Th17 cell differentiation even in the presence of anti-
IL-2 neutralizing antibody in vitro [11]. Activation of STAT1
signaling is induced by inflammatory cytokines such as IL-
27, IFN-𝛾, and type I IFN and inhibits Th17 differentiation
in vitro [31]. However, the inhibitory mechanism of Th17
differentiation by TL1A was independent of activation of
STAT1 signaling as well as IL-2 signaling [11]. Further, DR3
is dispensable for Th1, Th2, and Th17 differentiation from
näıve CD4+ T cells in vitro [24]. Thus, the role of TL1A
in Th17 differentiation is still controversial in vitro. How-
ever, TL1A transgenic mice [26, 27], and Th17-mediated
autoimmune disease model mice, experimental autoimmune
encephalomyelitis [13] and dextran-sulfate-induced chronic
colitis [32], show that TL1A-DR3 interaction could positively
regulate Th17 cell function in vivo. Further research will be
required to elucidate the regulatorymechanism of TL1A-DR3
interaction for Th17 cell function in vitro and in vivo.
3.3. Th2. TL1A-DR3 interaction is involved in Th2- as well
as Th1- and Th17-mediated immune responses. Transgenic
mice that constitutively express TL1A specifically in T cells or
dendritic cells develop Th2 cytokine IL-13-dependent small
intestinal inflammation [26, 27]. Intranasal immunization
with ovalbumin (OVA) together with TL1A in mice induces
Th2-mediated immune responses, including OVA-specific
IgG1 antibody production in serum, IgA antibody production
in mucosal tissues, and the production of Th2 cytokines IL-
4 and IL-5 from OVA-restimulated splenocytes in vitro [33].
Studies have shown that in DR3-deficient mice, or following
blockade of TL1A-DR3 interaction by TL1A neutralization
antibodies, OVA-induced lung inflammation is attenuated
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andTh2 cytokines IL-4, -5, and -13 production is reduced in a
mousemodel of asthma [10, 24]. Inmice with small intestinal
inflammation or OVA-induced lung inflammation, NKT
cells, activated and memory CD4+ T cells, or eosinophils
are likely to be a main source of the Th2 cytokines that are
induced by the TL1A-DR3 signaling pathway [10, 24, 26, 27],
suggesting that TL1A-DR3 signaling in these cells might be a
therapeutic target in asthma and ulcerative colitis.
3.4. Treg Cells. TL1A transgenic mice show the proliferation
and activation of Treg cells in the secondary lymphoid organs
and the small intestinal lamina propria [26, 27, 34]. Although
exogenous TL1A itself does not affect either n-Treg or i-Treg
proliferation in vitro, it promotes Treg cell proliferation in
the presence of antigen presenting cells with TCR stimulation
both in vitro and in vivo [13, 35], suggesting that TCR
signaling is required for costimulation of Treg cells as well as
conventional T cells by TL1A. Agonistic anti-DR3 antibodies
expand the proliferation of preexisting Treg cells in a manner
dependent on TCR and IL-2 signaling in vivo, and the
expanded Treg cells inhibit OVA-induced lung inflammation
[12]. Although Treg cells derived from TL1A-treated mice
have highly suppressive activity ex vivo, both exogenous
TL1A and agonistic anti-DR3 antibodies directly inhibit the
suppressive activity of Treg cells in vitro [12, 35]. Treg cells
derived frommice that constitutively express TL1A under the
CD11 promoter attenuate the ability to suppress conventional
T cells in vitro [26], whereas Treg cells derived frommice con-
stitutively expressing TL1A under the CD2 promoter main-
tain their suppressive ability [27]. These results suggest that
the effect of TL1A-DR3 interaction on T cells might be highly
dependent on experimental conditions in vitro or the context
of the immune response that is being modulated in vivo.
3.5. NK and NKT Cells. TL1A and agonistic anti-DR3 anti-
bodies synergize with IL-12 and IL-18 to augment IFN-𝛾
production in NK cells and NKT cells as well as T cells
[28].The fold-induction of IFN-𝛾 production by the addition
of TL1A is significantly lower in NK cells and NKT cells
than in CD4+ T cells and CD8+ T cells. The combination
of IL-12 and IL-18 drastically increased the DR3 expression
in NK cells but minimally in T cells. These data suggest that
the augmentation of IL-12/IL-18-induced IFN-𝛾 in response
to TL1A is differentially induced in T cells and NK cells.
TL1A also enhances IL-12/IL-18-induced NK cell cytolytic
activity, which is independent of IFN-𝛾 production [36],
suggesting that TL1A might be an attractive molecule for
tumor therapy. Agonistic anti-DR3 antibodies costimulate
the proliferation and IL-13 production of NKT cells stim-
ulated with 𝛼-galactoceramide or anti-CD3 antibodies [10].
NKT-deficient mice, which are resistant to OVA-induced
allergic lung inflammation, restore the lung inflammation
upon adaptive transfer of wild-type NKT cells, but not after
transfer of dominant negative DR3 transgenic NKT cells,
suggesting that DR3 signals in NKT cells play an important
role for triggering lung inflammation [10].
3.6. B Cells. In contrast to T cells, there have been few reports
on the significance of TL1A-DR3 interaction in B cells. Mem-
brane-bound TL1A expression on resting B cells was found
to be at very low levels in mice [27]. TL1A expression is not
induced in B cells either during resting or activated con-
ditions. In vitro, TL1A directly reduces B-cell proliferation
induced by anti-IgM antibodies and IL-2, whereas it does not
affect B-cell proliferation induced by a combination of anti-
IgM antibodies and other B-cell-specific stimulators, namely,
CpG oligodeoxynucleotide and CD40 ligand [14].
Collectively, these reports indicate that TL1A-DR3
interaction exerts pleiotropic effects on adaptive immune
cells, including their activation, proliferation, differentiation,
cytokine production, and maintenance.
4. Association of TNFSF15 Gene
Polymorphisms with Autoimmune
and Inflammatory Diseases
To examine the association of TNFSF15 gene polymorphisms
with autoimmune diseases, Yamazaki et al. performed a
genomewide case-control study and found that TNFSF15
gene polymorphisms are associated with the susceptibility
to CD in a Japanese population as well as IBD in a Euro-
pean population [37]. Subsequent replication studies and
genomewide association studies have revealed that TNFSF15
is only one gene that is associated with CD or IBD in both
Asian and Caucasian population [38–45]. TNFSF15 gene
polymorphisms are also associated with the severity of CD
and IBD in Japanese and Caucasian population, respectively
[46–48]. TNFSF15 haplotypes A and B (which consist of five
polymorphisms: rs3810936, rs6478108, rs6478109, rs7848647,
and rs7869487) are risk and protective factors, respectively,
for susceptibility in both Asian CD and Caucasian IBD
patients [37, 39, 49], and haplotype B is a risk factor for sever-
ity and antibody status for E. coli outer membrane porin C
in Jewish CD patients [49, 50]. A polymorphism of TNFSF15
haplotype A increases promoter activity in stimulated T
cells [51], whereas TNFSF15 haplotype B is associated with
increased soluble and membrane TL1A expression in some
Jewish CD patients [50]. In addition to IBD, TNFSF15 gene
polymorphism rs4263839 is associated with susceptibility
to irritable bowel syndrome and ankylosing spondylitis in
Caucasians [52, 53], andwe recently found thatTNFSF15 gene
polymorphism rs4979462 is associated with susceptibility to
PBC in a Japanese population [54]. These findings suggest
that TNFSF15 gene polymorphisms contribute to altered
TL1Aproduction, leading to the pathogenesis of autoimmune
and inflammatory diseases. In addition to TNFSF15, poly-
morphisms of IL-23R and IL-12A/IL-12RB2 are associated
with susceptibility to IBD [55, 56] and PBC [57], respectively.
TL1A and IL-23 or IL-12 synergistically induceTh1- andTh17-
effector cells, implicating the TL1A-IL12/IL-23 pathway in the
pathogenesis of both IBD and PBC. Zhang et al. reported
that TNFSF15, NOD, and IL-23R are susceptibility genes for
leprosy in a Chinese population [58, 59].These genes are also
susceptibility genes in CD, suggesting that CD and leprosy
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may share a common disease pathway, in particular innate
immunity and inflammatory responses.
5. Role of TL1A and DR3 in Autoimmune
and Inflammatory Diseases
5.1. RA. TL1A expression is elevated in the serum, synovial
fluid, and synovial tissues of RA patients, in particular
patients who are positive for rheumatoid factor (RF). Its
expression is correlated with the severity of RA [6, 60].
DR3 gene duplication is more prevalent in RA patients as
compared to healthy subjects [61]. Immunohistochemical
staining found that TL1A-positive cells in the synovial tis-
sue of RA patients, in particular RF-positive patients, are
positive for CD14 and CD68, which are surface markers of
macrophages and monocytes [6]. TL1A is induced in human
synovial fibroblasts stimulated with TNF-𝛼 and IL-1𝛽 [4] and
in monocytes stimulated with insoluble immune complexes
derived from RA patients [6]. TL1A induces T cells to secrete
TNF-𝛼 and IL-17 under TCR stimulation or Th17 polar-
ization conditions, respectively [4], and it synergizes with
IFN-𝛾 and augments the production of CXCL8 and matrix
metalloproteinase 9 in the human monocytic cell line THP-
1 [62]. These inflammatory cytokines and chemokines are
associated with RA pathology, and therefore it is possible that
TL1A and these inflammatory cytokines form a vicious loop
that aggravates RA pathogenesis. Indeed, administration of
the anti-TNF-𝛼monoclonal antibody adalimumab decreases
serum TL1A levels in RA patients [60]. In a mouse model,
TL1A administration exacerbated collagen-induced arthritis
(CIA) and increased the germinal center formation of spleen
and serum anticollagen autoantibodies that are pathogenic in
RA [4]. DR3 knockout mice show resistance to development
of adverse bone pathology in experimental antigen-induced
arthritis (AIA), and TL1A promotes osteoclastogenesis in a
DR3-dependent manner in AIA model mice [63], suggesting
that DR3 is involved in the generation of osteoclasts at site of
bone pathology. Collectively, TL1A-DR3 interaction forms a
part of the inflammatory cytokine network and contributes
to RA pathogenesis by promoting osteoclastogenesis and
the production of inflammatory cytokines and autoantibod-
ies. Furthermore, administration of neutralizing antibodies
against TL1A ameliorated both AIA and CIA [63], suggesting
that the TL1A-DR3 pathway may be a potential therapeutic
target in RA patients.
There has been growing evidence that RA patients are at
elevated risk for cardiovascular disease [64]. It was reported
that TL1A and its receptors are correlatedwith atherosclerosis
[65]. TL1A regulates the expression of genes implicated in
the uptake (scavenger receptors such as SR-A, SR-B1, and
CD36) and efflux of cholesterol (ABCG-1, ABCA-1, and
ApoE), leading to promotion of foam cell formation in
human macrophage [65]. This TL1A-induced macrophage
foam cell formation is dependent on DR3. DR3 itself also
promotes macrophage foam cell formation by regulating the
expression of genes implicated in the uptake and efflux of
cholesterol [65]. In addition, it was recently reported that
elevated serum TL1A at baseline positively correlates with
the progression of atheromatic plaque height in RA patients
[66]. A combination of low TL1A and undetectable DcR3
levels in serum at the baseline correlates with decrease of
new atheromatic plaques in carotid arteries and/or femoral
arteries of RA patients over a follow-up period of 3.5 years,
suggesting that serum TL1A and DcR3 levels might predict
a preserved atherosclerosis profile in carotid and/or femoral
arteries. The expression of DR3 mRNA but neither TL1A nor
DcR3 shows a trend to evaluation in atheromatous plaques of
arterial tissue. Collectively, these data highlights that TL1A-
DR3/DcR3 signaling is involved in chronic inflammation and
atherosclerosis.
5.2. Human IBD. In IBD patients, TL1A expression is
increased in both serum and intestinal tissues and is cor-
related with the disease activity [67–69]. DR3 expression is
also increased in lymphocytes, in particular T cells, in the
intestinal lamina propria in these patients [68]. Interestingly,
TL1A-expressing cells in the lamina propria are macrophages
and CD4+ or CD8+ T cells in CD patients, whereas they are
mainly plasma cells inUCpatients [68].Thediversity of TL1A
expression might reflect differences in the pathogenesis of
CD and UC. TL1A expression is increased only in lamina
propria CD14+ macrophages (but not peripheral monocytes
or monocyte-derived macrophages) in CD patients but
not in UC patients or healthy subjects. The membrane-
bound expression of TL1A is induced in lamina propria
CD14+ macrophages stimulated by commensal bacteria such
as E. coli [70]. In UC, IgG-producing plasma cells were
found to infiltrate areas of mucosal inflammation, and IgG
immune complex stimulation increased TL1A expression
in macrophages in the lamina propria [71]. These findings
indicate that mononuclear phagocytes are likely to be amajor
source of TL1A in inflamed loci in the intestines of IBD
patients. In CD patients, exogenous TL1A and agonistic anti-
DR3 antibodies augment IFN-𝛾 production in lamina propria
mononuclear cells as well as peripheral blood mononuclear
cells [68, 69]. TL1A synergizes with IL-12/IL-18 and induces
IFN-𝛾 production in lamina propria CCR9+ T cells derived
from CD patients, which is thought to be implicated in the
pathogenesis of CD [72]. Exogenous TL1A and IL-23 syner-
gistically induce IFN-𝛾 and IL-17 secretion in lamina propria
CD4+ T cells. TL1A enhances the differentiation of IL-17-
and IFN-𝛾/IL-17-producing Th17 cells when näıve CD4+ T
cells are stimulatedwith lamina propriamacrophages derived
fromCD patients [70].These reports demonstrate that TL1A-
DR3 interaction may contribute to Th1- and Th17-mediated
responses that are characteristic of CD.
5.3. IBD Mouse Model. TL1A is increased in the intestines of
IBD model mice, including dextran-sodium-sulfate (DSS-)
induced chronic colitis mice and TNFΔARE chronic ileitis
mice. Its major source is likely to be dendritic cells in
mesenteric lymph nodes and small intestinal lamina propria
mononuclear cells [25, 32]. Mice with constitutive TL1A
expression in antigen-presenting cells and T cells show
intestinal inflammation and colonic fibrosis with a high
percentage of T cells that are positive for CCR9 and CCR10,
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both of which are gut-homing chemokines in T cells [34].
As with TL1A, DR3 expression is increased in DSS-induced
chronic colitis mice, and its transmembrane splicing variant
is increased in correlation with inflammation in chronic
ileitis mice, TNFΔARE mice, and SAMP1/Yit Fc mice [25,
32]. Administration of blocking anti-TL1A monoclonal anti-
bodies inhibits DSS-induced colonic inflammation in mice
[32], and DR3-deficient mice are protected from intestinal
inflammation even after colitis induction [27]. In mice with
2,4,6-trinitrobenzenesulfonic acid- (TNBS-) induced colitis,
colonic inflammation is inhibited by administration of anti-
TL1A or anti-DR3 antibodies [27].These reports demonstrate
that TL1A-DR3 interaction plays an important role in the
pathogenesis of these chronic intestinal inflammatory con-
ditions in mice. TL1A synergizes with IL-12 or IL-23 and
induces both IFN-𝛾 and IL-17 secretion in CD4+ T cells
derived from gut-associated lymphoid tissue (GALT) of DSS-
induced chronic colitis mice [32]. IL-23 itself or IL-23 in
combination with TL1A induces IFN-𝛾/IL-17 double-positive
CD4+ T cells that are known to be colitogenic [32]. Sustained
TL1A expression in T cells or dendritic cells promotes goblet
cell and Paneth cell hyperplasia in the small intestine in
mice [26, 27, 34]. Hyperplasia of goblet cells and Paneth
cells is associated with elevated Th2 cytokine production
[73, 74]. In mice with sustained TL1A expression, IL-13 and
IL-17 expression is increased in mesenteric lymph node cells,
ileum, and CD4+ T cells isolated from the lamina propria.
Administration of antagonistic anti-IL13 antibodies but not
anti-IL17 antibodies attenuates intestinal inflammation in
mice constitutively expressing TL1A [27], suggesting that IL-
13 plays an important role in the small intestinal inflam-
mation induced by sustained TL1A expression on T cells or
dendritic cells. Although agonistic anti-DR3 antibodies and
glycosphingolipid enhance the production of Th2 cytokines
IL-13 and IL-4 in NKT cells [10], mice with sustained TL1A
expression and small intestinal inflammation show decreased
NKT cells and increased activated andmemory CD4+ T cells,
suggesting that in thesemice themajor source of IL-13 is likely
to be activated and memory T cells [26, 27]. In human, CD is
associated with the Th1/Th17 cytokines IL-12 and IL-23, and
UC with the Th2 cytokine IL-13 [75]. Taken together, these
findings in IBD model mice provide evidence that TL1A-
DR3 interaction may contribute to both Th1/Th17 and Th2
signaling pathways in human IBD.
5.4. Psoriasis. Bamias et al. reported an association of TL1A
and its two receptors with psoriasis [76]. TL1A is mainly
expressed in keratinocyte, basal cells, vascular cells, and
infiltrating inflammatory cells of psoriatic skin but is rarely
expressed in those of normal skin. DR3 and DcR3 are
expressed in normal skin and are upregulated in psoriatic
skin. The expression levels of TL1A and its two receptors
are upregulated in lesional skin as compared to nonlesional
skin in psoriasis patients, suggesting that TL1A and its two
receptors may be involved in the pathogenesis of psoriasis.
Immunohistochemical staining shows that TL1A localizes at
nuclear region in inflammatory and fibroblast-like cells in
psoriasis patients, although previous studies reported that
TL1A localizes at cytoplasmic region in inflamed tissues
of several autoimmune diseases [6, 68]. In this paper, the
unique nuclear location is also confirmed in synoviocytes and
inflammatory cells in RA patients. Further study is needed
to show the significance of nuclear TL1A localization. TL1A
transgenic mice develop chronic intestinal inflammation and
aminority of themice also develop ulcerative skin lesions and
arthritis. Concurrent rate among IBD, RA, and psoriasis is
high in human.These reportsmight provide the evidence that
TL1A is one of common denominators of gut, joint, and skin
inflammation.
5.5. PBC. We recently found that TL1A expression is
increased in both serum and liver tissues of PBC patients.
In the liver, TL1A expression is positive for infiltrating mon-
onuclear cells, endothelial cells, Kupffer cells, and biliary
epithelial cells. SerumTL1A levels are decreased in early-stage
but not late-stage patients being treatedwith ursodeoxycholic
acid, the only therapeutic drug for PBC approved by the
Food and Drug Administration, suggesting that TL1A has a
potential to be a new serum marker and therapeutic target
for PBC [77].
6. The Association of DcR3 with Autoimmune
and Inflammatory Diseases
DcR3, also known as TR6, and M68, is a member of the
TNFRSF. DcR3 consists of 300 amino acids lacking a trans-
membrane domain of TNFRSF and be released as secreted
protein. DcR3 functions as a decoy receptor for TL1A as
well as FasL and LIGHT and inhibits these ligands mediated
apoptosis and lymphokine secretion [78–81]. DcR3 is induced
in human antigen-presenting cells such as monocytes and
myeloid dendritic cells and intestinal epithelial cells lines by
lipopolysaccharide or lipoteichoic acid and is also induced
in human dermal microvascular endothelial cells by TNF-𝛼
and IL-1𝛽 [82, 83]. DcR3 modulates the differentiation and
maturation of monocyte, macrophage, and dendritic cells,
polarization of näıve T cells intoTh-2 immune response [84],
and the negative regulation for activation of B cells by TLR
ligands [85]. DcR3 is rarely detectable in serum of healthy
subjects, whereas its expression is increased in that of various
autoimmune and inflammatory diseases such as IBD [67, 86],
SLE [78], RA [60], PBC [77], silicosis [87], viral infections
[82], renal failure [88], and atopic dermatitis [89] as well as
cancer [90]. DcR3 is not found in mouse genome, suggesting
that additional complexity of TL1A-DR3 pathway in human
as compared to mouse. DcR3 protects the development of
autoimmune diabetes [91, 92], IgA nephropathy [93], and
crescent glomerulonephritis [94] model mice, while DcR3-
transgenic mice develop SLE-like syndrome [95]. These
reports suggest that DcR3 also plays an important role in the
pathogenesis of autoimmune and inflammatory diseases.
7. Conclusion
TL1A expression is transiently induced by inflammatory
cytokines, TLR ligands, enteric bacteria, and Fc𝛾R
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Figure 1: TL1A connects innate immune responses to adaptive immune responses and is critically involved in the induction of autoimmune
and inflammatory diseases.
crosslinking in antigen-presenting cells or non-immune
cells. Although TL1A was initially characterized as a
costimulator for inducing cell proliferation and cytokine
secretion in T cells, there is growing evidence that TL1A
has pleiotropic effects such as cell death, differentiation, and
maintenance of lymphocytes, as well as osteoclastogenesis
and atherosclerosis. Increased TL1A expression and/or TL1A
(TNFSF15) gene polymorphisms are associated with the
pathogenesis of various autoimmune and inflammatory
diseases. Analysis of murine models of autoimmune diseases
and TL1A or DR3 transgenic mice suggests that TL1A-DR3
interaction plays an important role in local inflammation of
T-cell-dependent autoimmune diseases.Thus, TL1A connects
innate immune responses to adaptive immune responses and
is critically involved in the induction of autoimmune and
inflammatory diseases (Figure 1), suggesting that inhibition
of TL1A-DR3 interaction could be an effective therapeutic
strategy for ameliorating local inflammation in target organs
of individuals with autoimmune diseases.
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